Zealand Pharma A/S (NASDAQ:ZEAL) headquartered in Copenhagen, will host a conference call for the investment community to discuss the 3Q20 financial results on 12th November 2020 at 10:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.zealandpharma.com
To participate on the live call, please dial +1 631 510 7495 Toll Free, when prompted, enter passcode 1296466
Earnings Expectation
Zealand Pharma A/S is reporting third quarter financial results on Thursday 12th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ZEAL is expected to report 3Q20 loss of $ 0.89 per share from revenue of $ 11.35 million. For the full year, analysts anticipate top line of $ 64.19 million, while looking forward to loss of $ 2.75 per share bottom line.
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua.
